NYSE · Medical - Devices

GMED (GMED) Stock

$80.19 +2.48% NYSE: GMED Healthcare

Valuation

MetricValue
Price$80.19
Market Cap$10.81B
P/E Ratio20.18
P/B Ratio2.33
P/S Ratio3.48
EPS (TTM)$3.92
52-Week High$101.40
52-Week Low$51.79
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE11.76%
ROA10.15%
ROCE10.50%
Gross Margin16.33%
Operating Margin16.33%
Net Margin18.92%
Debt/Equity0.02
Current Ratio4.27

Annual Financials (USD)

Metric20212022202320242025
Revenue$958.0M$1.0B$1.6B$2.5B$2.9B
Operating Profit$172.0M$228.0M$133.0M$166.0M$480.0M
Net Profit$149.0M$190.0M$123.0M$103.0M$538.0M
EPS$1.44$1.85$1.07$0.75$3.92
Op Margin17.9%22.3%8.5%6.6%16.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.0B$2.1B$5.1B$5.3B$5.3B
Total Liabilities$216.0M$230.0M$1.1B$1.1B$730.0M
Cash$193.0M$150.0M$467.0M$784.0M$526.0M
Borrowings$0$6.0M$520.0M$537.0M$119.0M

Latest News

ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now? Zacks · Jul 10, 2026 Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now? Zacks · Jul 10, 2026 Should You Continue to Hold OMCL Stock in Your Portfolio Now? Zacks · Jul 9, 2026 GE HealthCare & Mayo Clinic Unite to Advance Cancer Theranostics Zacks · Jul 9, 2026 Here's Why You Should Hold Avantor Stock in Your Portfolio for Now Zacks · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$276.0M$178.0M$243.0M$521.0M$753.0M
Investing Cash Flow$-433.0M$-184.0M$225.0M$-291.0M$-520.0M
Financing Cash Flow$54.0M$-110.0M$-232.0M$-28.0M$-679.0M
Net Cash Flow$-46.0M$-43.0M$317.0M$317.0M$-258.0M
Free Cash Flow$219.0M$104.0M$165.0M$405.0M$589.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA17.10
FCF Yield5.62%
Quick Ratio2.95
Interest Coverage—
Return 1Y46.64%
Return 3Y23.20%
Return 5Y-6.36%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGNAlign Technology, Inc. $169.29 +1.36% 27.86 $12.12B 0.00%
ATR $136.77 +2.10% 19.32 $8.73B 1.66%
BIO $330.54 +4.47% 10.29 $8.94B 0.00%
DVADaVita Inc. $236.58 +0.48% 23.20 $15.18B 0.00%
GRFSGrifols, S.A. $7.27 -0.27% 14.60 $6.15B 1.24%

About GMED

GMED is led by CEO Keith W. Pfeil, employs 6,000 people, headquartered in Audubon, US, publicly traded since 2012.

GMED stock trades at $80.19 with a market capitalization of $10.81B. The stock is valued at a price-to-earnings (P/E) ratio of 20.18, price-to-book of 2.33, price-to-sales of 3.48. Over the past 52 weeks the stock has ranged between $51.79 and $101.40, and currently trades 20.9% below its 52-week high.

On profitability, GMED generates a return on equity (ROE) of 11.76%, return on capital employed of 10.50%, an operating margin of 16.33%, a net profit margin of 18.92%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides